We are honored to invite Dr. Bailey to introduce a novel approach that leverages cytokine-pathway editing to enhance CAR-T cell performance.
Join us to explore how deleting the IFNγ receptor (IFNγR) in CAR-T cells can uncouple their efficacy from attrition, leading to improved and lasting antitumor results in various solid tumor models. This strategy also highlights that engineering choices must consider the specific costimulatory domain (CD28 vs. 4-1BB) and that subset-aware strategies are crucial for optimizing persistence and function. Applying these principles will help create more durable, solid-tumor–ready CAR-T therapies for clinical use.
During this webinar, we will discuss the following key points:
- How cytokine-pathway editing (e.g., IFNγ sensing) can be leveraged to uncouple efficacy from attrition.
- Why engineering choices must be contextualized by costimulatory domain, as CD28 and 4-1BB parse cytokine cues differently.
- How subset-aware strategies are essential to optimize persistence and function for CAR-T cells.
